BIIB News 327.58 09/18/2014 04:31:15 Biogen Idec Inc (BIIB)
Post# of 273322
Posted On: 09/18/2014 5:31:09 AM
Biogen Idec Inc (BIIB) 327.58 $BIIB
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:30PM CDT
Sanofi's (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:30PM CDT
Biogen Idec Inc. (BIIB) announced encouraging data from the phase III ADVANCE study on Plegridy in patients suffering from relapsing+remitting multiple sclerosis.
Critical Alerts For U.S. Bancorp, Nuverra Environmental Solutions, Biogen, Deere and Philip Morris International Released By InvestorsObserver
PR Newswire - Fri Sep 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for USB, NES, BIIB, DE and PM.
Why Biogen Idec Inc's Stock is Up 17% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 12, 7:43AM CDT
Source: Biogen Idec Biogen Idec's stock has returned about 17% this year. That's good enough to outpace the S&P 500 index's 8.9% return, but not quite as good as the Nasdaq Biotechnology index's 19% return. Since Biogen is one of...
Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA(TM) (Daclizumab High-Yield Process)
Business Wire - Fri Sep 12, 6:30AM CDT
--a^' First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting -
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:55PM CDT
Novartis (NVS) has presented encouraging data on MS drug, Gilenya, from a follow-up extension study, LONGTERMS, at the Joint ACTRIMS-ECTRIMS Meeting in Boston.
After Yesterday's Decline of 1.50%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $324.74 to a high of $332.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $325.99 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:30PM CDT
Sanofi's (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:30PM CDT
Biogen Idec Inc. (BIIB) announced encouraging data from the phase III ADVANCE study on Plegridy in patients suffering from relapsing+remitting multiple sclerosis.
Critical Alerts For U.S. Bancorp, Nuverra Environmental Solutions, Biogen, Deere and Philip Morris International Released By InvestorsObserver
PR Newswire - Fri Sep 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for USB, NES, BIIB, DE and PM.
Why Biogen Idec Inc's Stock is Up 17% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 12, 7:43AM CDT
Source: Biogen Idec Biogen Idec's stock has returned about 17% this year. That's good enough to outpace the S&P 500 index's 8.9% return, but not quite as good as the Nasdaq Biotechnology index's 19% return. Since Biogen is one of...
Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA(TM) (Daclizumab High-Yield Process)
Business Wire - Fri Sep 12, 6:30AM CDT
--a^' First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting -
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:55PM CDT
Novartis (NVS) has presented encouraging data on MS drug, Gilenya, from a follow-up extension study, LONGTERMS, at the Joint ACTRIMS-ECTRIMS Meeting in Boston.
After Yesterday's Decline of 1.50%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $324.74 to a high of $332.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $325.99 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
(0)
(0)